Your browser is no longer supported. Please, upgrade your browser.
Settings
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-8.01 Insider Own5.10% Shs Outstand75.79M Perf Week1.07%
Market Cap6.56B Forward P/E- EPS next Y-5.04 Insider Trans0.67% Shs Float70.59M Perf Month4.98%
Income-570.30M PEG- EPS next Q-1.36 Inst Own96.40% Short Float20.53% Perf Quarter-40.57%
Sales344.60M P/S19.05 EPS this Y-533.90% Inst Trans0.24% Short Ratio8.50 Perf Half Y-26.65%
Book/sh14.86 P/B5.83 EPS next Y32.60% ROA-34.90% Target Price187.86 Perf Year-37.59%
Cash/sh14.55 P/C5.95 EPS next 5Y-0.20% ROE-55.40% 52W Range72.05 - 158.80 Perf YTD-20.63%
Dividend- P/FCF- EPS past 5Y-10.60% ROI-23.60% 52W High-45.45% Beta2.17
Dividend %- Quick Ratio7.80 Sales past 5Y84.10% Gross Margin85.50% 52W Low20.22% ATR3.78
Employees499 Current Ratio8.80 Sales Q/Q28.80% Oper. Margin- RSI (14)53.70 Volatility3.48% 4.94%
OptionableYes Debt/Eq0.00 EPS Q/Q-124.00% Profit Margin- Rel Volume0.50 Prev Close85.77
ShortableYes LT Debt/Eq0.39 EarningsOct 30 AMC Payout- Avg Volume1.71M Price86.62
Recom1.70 SMA206.70% SMA50-4.88% SMA200-27.85% Volume894,275 Change0.99%
Aug-21-19Reiterated Needham Buy $196 → $170
Jul-09-19Reiterated Morgan Stanley Overweight $165 → $220
Jul-01-19Reiterated RBC Capital Mkts Outperform $188 → $220
Apr-12-19Initiated Evercore ISI Outperform
Mar-11-19Reiterated Credit Suisse Outperform $189 → $207
Oct-12-18Initiated Bernstein Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Sep-26-18Reiterated RBC Capital Mkts Outperform $187 → $200
Sep-14-18Resumed BofA/Merrill Buy $199
Sep-06-18Initiated Credit Suisse Outperform $178
Aug-01-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-21-18Reiterated Robert W. Baird Outperform $120 → $202
Jun-20-18Reiterated Needham Buy $109 → $204
Jun-19-18Reiterated H.C. Wainwright Buy $96 → $267
May-18-18Reiterated Goldman Buy $84 → $127
May-11-18Upgrade Barclays Equal Weight → Overweight $55 → $107
May-07-18Reiterated Needham Buy $75 → $109
May-07-18Reiterated H.C. Wainwright Buy $90 → $96
Mar-21-18Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-13-18Reiterated H.C. Wainwright Buy $75 → $92
Oct-21-19 08:03PM  SAREPTA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm Newsfile
07:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT ACCESSWIRE
07:40PM  SHAREHOLDER ALERT: SRPT MYGN CC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
06:50PM  OCTOBER 29 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
06:47PM  3 Stocks That Gurus, Insiders and Companies Are Buying GuruFocus.com
Oct-18-19 03:30PM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SRPT, TME and UBER ACCESSWIRE
03:00PM  Burford Capital Limited (BRFRF, BRFRY), Sarepta Therapeutics, Inc. (SRPT), & Canada Goose Holdings Inc. (GOOS) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Actions GlobeNewswire
11:15AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of SRPT, MGNX and TME ACCESSWIRE
10:37AM  Burford Capital Limited (BRFRF, BRFRY), Sarepta Therapeutics, Inc. (SRPT), & Canada Goose Holdings Inc. (GOOS) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Actions ACCESSWIRE
Oct-17-19 02:45PM  CLASS ACTION UPDATE for SRPT, MO and MYGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
02:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT ACCESSWIRE
Oct-16-19 07:30PM  SHAREHOLDER ALERT: SRPT MTCH WTRH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
05:31PM  SAREPTA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm Newsfile
05:04PM  OCTOBER 29 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
01:45PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of SRPT, MDP and TME ACCESSWIRE
10:36AM  Burford Capital Limited (BRFRF, BRFRY), Sarepta Therapeutics, Inc. (SRPT), & Canada Goose Holdings Inc. (GOOS) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Actions ACCESSWIRE
10:32AM  Earnings Preview: Sarepta Therapeutics (SRPT) Q3 Earnings Expected to Decline Zacks
09:30AM  CLASS ACTION UPDATE for COF, SRPT, CADE and WTRH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Oct-15-19 08:37PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Valaris, Sarepta Therapeutics, Canada Goose, and Meredith Corporation and Encourages Investors to Contact the Firm GlobeNewswire
04:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT GlobeNewswire
Oct-14-19 10:16AM  The Biotech Sector Is Lagging. Blame Gene Therapy Stocks, Analysts Say. Barrons.com
Oct-12-19 02:22PM  Hedge Funds Have Never Been This Bullish On Sarepta Therapeutics Inc (SRPT) Insider Monkey
Oct-11-19 06:50PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SRPT, TXT and TME ACCESSWIRE
05:35PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT ACCESSWIRE
03:35PM  CLASS ACTION UPDATE for SRPT, MGNX and CADE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
03:00PM  Burford Capital Limited (BRFRF, BRFRY), Sarepta Therapeutics, Inc. (SRPT), & Canada Goose Holdings Inc. (GOOS) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Actions GlobeNewswire
11:05AM  SHAREHOLDER ALERT: SRPT DBX TME: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
10:35AM  Burford Capital Limited (BRFRF, BRFRY), Sarepta Therapeutics, Inc. (SRPT), & Canada Goose Holdings Inc. (GOOS) - Class Action - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Oct-10-19 11:05AM  CLASS ACTION UPDATE for CVS, SRPT and DBX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:34AM  Burford Capital Limited (BRFRF, BRFRY), Sarepta Therapeutics, Inc. (SRPT), & Canada Goose Holdings Inc. (GOOS) - Class Action Reminder - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Oct-09-19 10:45AM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SRPT, MGNX and UBER ACCESSWIRE
08:00AM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta Therapeutics, Canada Goose, Meredith Corporation, and MacroGenics and Encourages Investors to Contact the Firm GlobeNewswire
Oct-08-19 12:33PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT GlobeNewswire
09:43AM  CLASS ACTION UPDATE for PS, IFF, SRPT and SNDL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
08:03AM  SAREPTA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm Newsfile
Oct-07-19 11:00AM  SHAREHOLDER ALERT: SRPT VRAY CADE: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE -8.26%
10:33AM  Burford Capital Limited (BRFRF, BRFRY), Sarepta Therapeutics, Inc. (SRPT), & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
08:48AM  Company News For Oct 7, 2019 Zacks
Oct-04-19 04:30PM  Does This Beleaguered Biotech Stock Have A Winner In Gene Therapy? Investor's Business Daily +8.50%
10:19AM  Sarepta Climbs as Gene Therapy Shows Promise in Early Study Bloomberg
09:29AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TWOU, SRPT, SNDL and MGNX GlobeNewswire
08:31AM  Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy GlobeNewswire
08:31AM  Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy Globenewswire Test
07:32AM  The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering Benzinga
06:28AM  Sarepta Shares Rise on Positive Gene Therapy Trial Results TheStreet.com
Oct-03-19 02:15PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of PS, SRPT and MDP ACCESSWIRE
01:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT ACCESSWIRE
Oct-02-19 09:25PM  SHAREHOLDER ALERT: SRPT MDP MGNX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
09:07PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta Therapeutics, Canada Goose, Meredith Corporation, and MacroGenics and Encourages Investors to Contact the Firm GlobeNewswire
12:00PM  3 Pharma Stocks at Risk for Downgrades Schaeffer's Investment Research
Oct-01-19 07:38PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT GlobeNewswire
06:31AM  With eyes on IPO, muscular dystrophy startup names new CEO American City Business Journals
Sep-30-19 06:03PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-29-19 10:47AM  CLASS ACTION UPDATE for ABMD, SRPT and TME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
09:31AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT ACCESSWIRE
Sep-27-19 05:00PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CAH, SRPT and TME ACCESSWIRE
03:00PM  Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
02:00PM  CLASS ACTION UPDATE for CAH, SRPT and SNDL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
12:30PM  SAREPTA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm Newsfile
11:00AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CAH, VAL and SRPT ACCESSWIRE
10:36AM  Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Sep-26-19 04:54PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT CNW Group
Sep-25-19 08:50PM  SHAREHOLDER ALERT: CURLF SRPT DXC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
08:06PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nektar Therapeutics, Valaris, Sarepta Therapeutics, and Canada Goose and Encourages Investors to Contact the Firm GlobeNewswire
11:15AM  SHAREHOLDER ALERT: MMM CAH SRPT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
10:35AM  Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
08:30AM  Sarepta Therapeutics to Announce 9-Month Functional Results from the SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy GlobeNewswire
Sep-24-19 04:20PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT GlobeNewswire
11:18AM  Cramer Weighs In On PayPal, NextEra And More Benzinga
09:51AM  SHAREHOLDER ALERT: VNTR PS SRPT CADE: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
09:45AM  INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Sep-23-19 11:05PM  SAREPTA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm Newsfile
01:00PM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CARB, SRPT and VRAY ACCESSWIRE
12:12PM  CLASS ACTION UPDATE for CURLF, SRPT and FTCH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:34AM  Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Sep-20-19 03:20PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of JE, ABMD and SRPT ACCESSWIRE
03:00PM  GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
11:20AM  CLASS ACTION UPDATE for GTT, TWOU and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:44AM  GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Actions - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Sep-19-19 02:35PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MNK, VAL and SRPT ACCESSWIRE
02:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT ACCESSWIRE
09:41AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of GTT, SRPT, TXT and VRAY GlobeNewswire
Sep-18-19 08:01PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta Therapeutics, Canada Goose, and Meredith Corporation and Encourages Investors to Contact the Firm GlobeNewswire
10:42AM  GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
10:00AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NFLX, CARB, TWOU and SRPT GlobeNewswire
05:36AM  After Boston speech, Ex-FDA chief defends record on vaping in interview American City Business Journals
12:04AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Sarepta Therapeutics, Inc. to Contact the Firm GlobeNewswire
Sep-17-19 09:01PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT GlobeNewswire
12:30PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of MNK, SRPT and MDP ACCESSWIRE
10:21AM  INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
10:02AM  CLASS ACTION UPDATE for MNK, CAH, GVA and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
12:05AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm ACCESSWIRE
Sep-16-19 10:00PM  Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and Encourages Sarepta Investors to Contact the Firm Business Wire
05:20PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of PS, TWOU and SRPT ACCESSWIRE
04:20PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT ACCESSWIRE
11:05AM  SHAREHOLDER ALERT: GVA VAL SRPT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
10:41AM  GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Sep-15-19 11:05AM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CAH, IFF and SRPT ACCESSWIRE
Sep-14-19 07:20AM  SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Sep-13-19 11:46PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm Newsfile
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company's pipeline comprise SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA. It has collaboration agreements with Nationwide Children's Hospital to advance micro-dystrophin gene therapy program under the research and license option agreement; Galgt2, a gene therapy program for the treatment of DMD; and Neutrophin 3, a gene therapy program to treat Charcot-Marie-Tooth neuropathies. The company also has a license agreement with Lysogene to develop LYS-SAF302, a gene therapy for mucopolysaccharidosis IIIA; a license and option agreement with Lacerta to develop treatments for CNS-targeted and lysosomal storage diseases; and research collaboration and option agreement with Genethon to develop micro-dystrophin gene therapy products. In addition, it has a research agreement with Duke University to advance gene editing CRISPR/Cas9 technology for restoring dystrophin expression; a collaboration agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline; a strategic collaboration with Paragon Bioservices; and a strategic collaboration with CENTOGENE for the identification of patients with DMD in the Middle East and North Africa region. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Barry RichardDirectorSep 13Buy87.493,309289,5043,187,065Sep 16 08:00 AM
Barry RichardDirectorSep 12Buy87.491,691147,9503,183,756Sep 16 08:00 AM
BONNEY MICHAEL WDirectorSep 09Buy86.742,000173,4807,051Sep 09 02:18 PM
BEHRENS M KATHLEENDirectorSep 06Buy87.982,500219,950125,667Sep 06 02:13 PM
BEHRENS M KATHLEENDirectorSep 05Option Exercise7.805,00039,000123,167Sep 06 02:13 PM
Mahatme SandeshEVP, CFO & CBOAug 21Option Exercise23.85100,0002,385,000130,179Aug 22 07:20 PM
Barry RichardDirectorAug 20Buy99.325,000496,5933,182,065Aug 20 05:43 PM
Mahatme SandeshEVP, CFO & CBOAug 15Option Exercise24.739,754241,23230,179Aug 15 04:33 PM
Barry RichardDirectorAug 14Buy122.503,700453,2503,177,065Aug 14 04:38 PM
Barry RichardDirectorAug 12Buy122.501,300159,2503,173,365Aug 13 04:31 PM
INGRAM DOUGLAS SPresident & CEOAug 12Buy123.0716,2522,000,160432,197Aug 12 05:48 PM
Wigzell Hans Lennart RudolfDirectorMay 23Option Exercise7.8010,00078,00021,717May 24 08:03 PM
Wigzell Hans Lennart RudolfDirectorMay 23Sale120.0010,0001,200,00011,717May 24 08:03 PM
Mahatme SandeshEVP, CFO & CBOMar 19Option Exercise21.4615,486332,30819,354Mar 20 08:00 PM
Mahatme SandeshEVP, CFO & CBOFeb 07Option Exercise23.8565,0001,550,25073,649Feb 08 08:02 PM
Mahatme SandeshEVP, CFO & CBOFeb 07Sale145.0065,0009,425,0008,649Feb 08 08:02 PM
Howton David TSVP, General CounselFeb 01Option Exercise21.6521,500465,39149,571Feb 01 08:25 PM
Cumbo AlexanderSVP, Chief Commercial OfficerFeb 01Option Exercise22.547,500169,03530,266Feb 01 08:27 PM
Cumbo AlexanderSVP, Chief Commercial OfficerFeb 01Sale140.0015,0002,100,00015,266Feb 01 08:27 PM
Howton David TSVP, General CounselFeb 01Sale140.0030,0004,200,00019,571Feb 01 08:25 PM
Mahatme SandeshEVP, CFO & CBOJan 31Option Exercise23.8521,198505,57229,847Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 31Sale130.7221,1982,771,0038,649Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 30Option Exercise18.2743,802800,07752,451Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 30Sale130.0043,8025,694,2608,649Feb 01 08:24 PM
Wigzell Hans Lennart RudolfDirectorNov 01Option Exercise8.946,66759,60316,751Nov 02 06:01 PM
Wigzell Hans Lennart RudolfDirectorNov 01Sale140.506,667936,71410,084Nov 02 06:01 PM
BEHRENS M KATHLEENDirectorOct 31Option Exercise3.9610,00039,600126,534Nov 02 06:00 PM
BEHRENS M KATHLEENDirectorOct 31Sale131.7110,0001,317,100116,534Nov 02 06:00 PM
INGRAM DOUGLAS SPresident & CEOOct 30Buy120.3916,6952,009,872415,945Oct 30 07:05 PM
Mahatme SandeshEVP, CFO & CBOOct 24Option Exercise14.8889,4001,330,389128,185Oct 26 06:43 PM
Mahatme SandeshEVP, CFO & CBOOct 24Sale127.74107,52413,735,11620,661Oct 26 06:43 PM